Related Experiment Video

Updated: Jan 30, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

411

Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer

Sara A Spencer1, Angela C Riley1, Adia Matthew1

  • 11 State University of New York, Binghamton, NY, USA.

The Annals of Pharmacotherapy
|January 15, 2019
PubMed
Abstract

Insights

Brigatinib offers a survival benefit for some patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (NSCLC) who progressed on crizotinib, despite potential side effects. This review covers its use in ALK-positive NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Anaplastic lymphoma kinase (ALK) gene rearrangements define a subset of non-small-cell lung cancer (NSCLC).
  • Crizotinib resistance is a significant challenge in ALK-positive NSCLC management.
  • Brigatinib has emerged as a targeted therapy option for advanced ALK-positive NSCLC.

Purpose of the Study:

  • To comprehensively review the pharmacology, pharmacokinetics, efficacy, safety, and clinical utility of brigatinib.
  • To evaluate brigatinib's role in treating patients with ALK-positive NSCLC, particularly those resistant to or intolerant of crizotinib.
  • To discuss brigatinib's dosing, administration, and potential drug interactions.

Main Methods:

  • A literature search was performed on PubMed using keywords 'brigatinib' and 'ALK positive NSCLC' from January 2013 to November 2018.
  • English-language articles evaluating brigatinib were analyzed for this review.
  • Data synthesis focused on clinical trial outcomes, adverse events, and therapeutic positioning.

Main Results:

  • Brigatinib received accelerated approval for metastatic ALK-positive NSCLC patients progressing on or intolerant to crizotinib.
  • The recommended dosage is 90 mg once daily, increasing to 180 mg once daily if tolerated.
  • Common adverse effects include nausea, fatigue, diarrhea, and hypertension; serious events involved pulmonary issues.

Conclusions:

  • Brigatinib demonstrates efficacy in overcoming crizotinib resistance and exhibits CNS penetration properties.
  • It offers a survival advantage of approximately one year for a subset of NSCLC patients.
  • Careful monitoring for side effects is essential during brigatinib treatment.
Keywords:
anaplastic lymphoma kinase (ALK)brigatinibnon–small-cell lung cancer (NSCLC)tyrosine kinase inhibitor

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Electrotaxis Studies of Lung Cancer Cells using a Multichannel Dual-electric-field Microfluidic Chip08:35

Electrotaxis Studies of Lung Cancer Cells using a Multichannel Dual-electric-field Microfluidic Chip

Published on: December 29, 2015

9.2K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
667
Pleura of the Lungs01:13

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
7.2K